Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Azenta, Inc.AZTA · Entity 4724 | Interim CEO | September 22, 2026 | September 23, 2026 |
| HAEMONETICS CORPHAE · Entity 3953 | Director | July 24, 2026 | July 28, 2026 |
| Quanterix CorpQTRX · Entity 6649 | Director | January 02, 2025 | January 06, 2025 |
| REPLIGEN CORPRGEN · Entity 486 | Director | May 14, 2026 | May 18, 2026 |
| STANDARD BIOTOOLS INC.LAB · Entity 6116 | Director | October 20, 2023 | October 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Azenta, Inc.
Report date September 22, 2026 · Filed September 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CommonSEC Table I · non-derivative | Direct | 42,602 |
Reported balance
After 2026-09-22 transaction · row 1
1 source rowRow 1 · 2026-09-22 · Tax withholding · Disposed 1,456 · Balance 42,602 F1: Shares withheld by the Company to satisfy tax withholding obligations arising from the vesting and settlement on September 22, 2026, of 3,055 restricted stock units held by the Reporting Person. This transaction does not represent a sale of securities by the Reporting Person in the market. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the Company to satisfy tax withholding obligations arising from the vesting and settlement on September 22, 2026, of 3,055 restricted stock units held by the Reporting Person. This transaction does not represent a sale of securities by the Reporting Person in the market.
HAEMONETICS CORP
Report date July 24, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,538 |
Reported balance
After 2026-07-24 transaction · row 1
1 source rowRow 1 · 2026-07-24 · Grant · Acquired 2,538 · Balance 2,538 F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Quanterix Corp
Report date January 02, 2025 · Filed January 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,908 |
Reported balance
After 2025-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-01-02 · Grant · Acquired 7,435 · Balance 36,908 F1: Represents restricted stock units that vest as to 100% of the shares on December 31, 2025 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2: Includes 7,435 restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.76 · Expires 2035-01-02 | Direct | 15,821 |
Reported balance
After 2025-01-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-01-02 · Grant · Acquired 15,821 · Balance 15,821 F3: Represents non-qualified stock option to purchase 15,821 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. |
| Common StockSEC Table I · non-derivative | IndirectHeld by trust | 254,633 |
Reported balance
Holding disclosure · report date 2025-01-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 254,633 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest as to 100% of the shares on December 31, 2025 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock.
F2: Includes 7,435 restricted stock units.
F3: Represents non-qualified stock option to purchase 15,821 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy.
REPLIGEN CORP
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,581 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 995 · Balance 6,581 F1: Mr. Madaus was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.38 · Expires 2036-05-14 | Direct | 2,239 |
Reported balance
After 2026-05-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-14 · Grant · Acquired 2,239 · Balance 2,239 F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. |
| Common StockSEC Table I · non-derivative | IndirectBy Martin D. Madaus 2011 Revocable Trust | 1,800 |
Reported balance
Holding disclosure · report date 2026-05-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,800 |
| Common StockSEC Table I · non-derivative | IndirectSpouse Trust | 11 |
Reported balance
Holding disclosure · report date 2026-05-14 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 11 |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Madaus was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
STANDARD BIOTOOLS INC.
Report date October 20, 2023 · Filed October 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 104,111 |
Reported balance
After 2023-10-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-10-20 · Grant · Acquired 1,574 · Balance 104,111 F1: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest 100% on December 15, 2023. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control. F2: The Restricted Stock Units were issued to the Reporting Person, who elected to take Restricted Stock Units in lieu of $4,000 in cash compensation for services as a committee memeber. The share price is based on the Fair Market Value as of the first date of quarterly trading window following the date on which the Reporting Person's new committe assignment was approved by the Board. F3: Represents Restricted Stock Units with respect to which the Reporting Person has deferred settlement as described above. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest 100% on December 15, 2023. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control.
F2: The Restricted Stock Units were issued to the Reporting Person, who elected to take Restricted Stock Units in lieu of $4,000 in cash compensation for services as a committee memeber. The share price is based on the Fair Market Value as of the first date of quarterly trading window following the date on which the Reporting Person's new committe assignment was approved by the Board.
F3: Represents Restricted Stock Units with respect to which the Reporting Person has deferred settlement as described above.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
HOLOGIC INC
Report date April 07, 2026 · Filed April 09, 2026
Section 16 reporting ended · disclosed 2026-04-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Disposition to issuer · Disposed 5,396 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F2: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectRevocable Trust | 0 |
Reported balance
After 2026-04-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-04-07 · Disposition to issuer · Disposed 5,445 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F3: As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.79 · Expires 2034-12-09 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Disposition to issuer · Disposed 1,016 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.36 · Expires 2035-02-26 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-07 · Disposition to issuer · Disposed 5,535 · Balance 0 F4: For Footnote (4), see Remarks below. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration").
F2: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
F3: As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
F4: For Footnote (4), see Remarks below.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2026 Filed Sep 23, 2026 14:24 UTC | Azenta, Inc. AZTA · Entity 4724 | Tax withholdingCommon | 1,456 | $34.28 | $49,911.68 |
DisclosureSEC source: 0001628280-26-063164 · wk-form4_1790173457.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,602 F1 · shares: Shares withheld by the Company to satisfy tax withholding obligations arising from the vesting and settlement on September 22, 2026, of 3,055 restricted stock units held by the Reporting Person. This transaction does not represent a sale of securities by the Reporting Person in the market. Read SEC document |
| September 14, 2026 Filed Sep 17, 2026 01:50 UTC | Azenta, Inc. AZTA · Entity 4724 | GrantCommon | 36,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-062354 · wk-form4_1789609812.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,058 F1 · shares: Grant of restricted stock units to the Reporting Person under the Company Equity Incentive Plan. No amount was paid upon grant of the units. Because the units are payable solely in shares of common stock, they are reported in Table I of this Form 4. The units are subject to time-based vesting and will vest 1/12 per month for twelve months. Read SEC document |
| July 24, 2026 Filed Jul 28, 2026 21:04 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,538 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000313143-26-000112 · form4.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,538 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 2,239 | $0.00 Strike: $103.38 | $0.00 |
DisclosureSEC source: 0001193125-26-228896 · ownership.xml · derivative · entry 4 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239 Underlying: Common Stock · 2,239 shares Expires 2036-05-14 F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-228896 · ownership.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,581 F1 · shares: Mr. Madaus was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:11 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 5,535 | Not disclosed Strike: $64.36 | Not disclosed |
DisclosureSEC source: 0000859737-26-000067 · form4.xml · derivative · entry 4 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,535 shares Expires 2035-02-26 F4 · price: For Footnote (4), see Remarks below. F4 · derivative.exercise_date: For Footnote (4), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:11 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerNon-qualified Stock Option (Right to Buy) · Derivative | 1,016 | Not disclosed Strike: $75.79 | Not disclosed |
DisclosureSEC source: 0000859737-26-000067 · form4.xml · derivative · entry 3 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,016 shares Expires 2034-12-09 F4 · price: For Footnote (4), see Remarks below. F4 · derivative.exercise_date: For Footnote (4), see Remarks below. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:11 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerCommon Stock | 5,445 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000859737-26-000067 · form4.xml · nonDerivative · entry 2 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Revocable Trust Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F3 · price: As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 21:11 UTC | HOLOGIC INC HOLX · Entity 12463 | Disposition to issuerCommon Stock | 5,396 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000859737-26-000067 · form4.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F2 · price: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:20 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 3,190 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000859737-26-000021 · form4.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,396 F1 · shares: Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 22:47 UTC | Azenta, Inc. AZTA · Entity 4724 | GrantRestricted Stock Unit · Derivative | 5,663 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001193125-26-041485 · ownership.xml · derivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,703 Underlying: Common Stock · 5,663 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Azenta's common stock. The units are fully vested upon grant but the Reporting Person elected to have the settlement deferred until the later of his attainment of age 65 or his separation from service from the company. F2 · price: Grant of Restricted Stock Units under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the units. F1 · derivative.exercise_date: Each restricted stock unit represents the right to receive one share of Azenta's common stock. The units are fully vested upon grant but the Reporting Person elected to have the settlement deferred until the later of his attainment of age 65 or his separation from service from the company. F1 · derivative.expiration_date: Each restricted stock unit represents the right to receive one share of Azenta's common stock. The units are fully vested upon grant but the Reporting Person elected to have the settlement deferred until the later of his attainment of age 65 or his separation from service from the company. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 16:47 UTC | REPLIGEN CORP RGEN · Entity 486 | PurchaseCommon Stock | 1,800 | $112.13 | $201,830.40 |
DisclosureSEC source: 0000950170-25-107084 · ownership.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Martin D. Madaus 2011 Revocable Trust Disclosed balance after: 1,800 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $111.72 to $112.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| May 15, 2025 Filed May 19, 2025 19:05 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,800 | $0.00 Strike: $123.26 | $0.00 |
DisclosureSEC source: 0000950170-25-074224 · ownership.xml · derivative · entry 3 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires 2035-05-15 F2 · derivative.exercise_date: Award vests in full on the earlier of May 15, 2026, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 15, 2025 Filed May 19, 2025 19:05 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 973 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074224 · ownership.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,586 F1 · shares: Mr. Madaus was awarded 973 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 15, 2026, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 07, 2025 Filed May 9, 2025 20:39 UTC | HOLOGIC INC HOLX · Entity 12463 | PurchaseCommon Stock | 5,445 | $55.24 | $300,760.02 |
DisclosureSEC source: 0001127602-25-013869 · form4.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Revocable Trust Disclosed balance after: 5,445 F1 · price: The price reported is the weighted average price per share. Shares were purchased in multiple transactions at prices ranging from $55.14 to $55.30 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. F2 · ownership.nature: These shares are held by a revocable trust, of which the Reporting Person is the settlor and trustee. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:20 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,535 | $0.00 Strike: $64.36 | $0.00 |
DisclosureSEC source: 0001127602-25-007248 · form4.xml · derivative · entry 2 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,535 Underlying: Common Stock · 5,535 shares Expires 2035-02-26 F3 · derivative.exercise_date: Options become exercisable on the date of the 2026 Annual Meeting of Stockholders. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:20 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 1,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-007248 · form4.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,206 F1 · shares: Represents restricted stock units which vest on the date of the 2026 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 21:10 UTC | Azenta, Inc. AZTA · Entity 4724 | GrantRestricted Stock Unit · Derivative | 4,040 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000950170-25-017898 · ownership.xml · derivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,040 Underlying: Common Stock · 4,040 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Azenta's common stock. The units are fully vested upon grant but the Reporting Person elected to have the settlement deferred until the later of his attainment of age 65 or his separation from service from the company. F2 · price: Grant of Restricted Stock Units under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the units. F1 · derivative.exercise_date: Each restricted stock unit represents the right to receive one share of Azenta's common stock. The units are fully vested upon grant but the Reporting Person elected to have the settlement deferred until the later of his attainment of age 65 or his separation from service from the company. F1 · derivative.expiration_date: Each restricted stock unit represents the right to receive one share of Azenta's common stock. The units are fully vested upon grant but the Reporting Person elected to have the settlement deferred until the later of his attainment of age 65 or his separation from service from the company. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:55 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (Right to Buy) · Derivative | 15,821 | $0.00 Strike: $10.76 | $0.00 |
DisclosureSEC source: 0001562180-25-000207 · primarydocument.xml · derivative · entry 3 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,821 Underlying: Common Stock · 15,821 shares Expires 2035-01-02 F3 · shares: Represents non-qualified stock option to purchase 15,821 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:55 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 7,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000207 · primarydocument.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,908 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2025 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 7,435 restricted stock units. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 21:21 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 342 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-029144 · form4.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342 F1 · kind: Represents restricted stock units which vest on the date of the 2025 Annual Meeting of Stockholders and are settled in shares of common stock. F2 · price: Restricted stock units are settled in shares of common stock on a one-for-one basis. Read SEC document |
| November 19, 2024 Filed Nov 19, 2024 21:00 UTC | Azenta, Inc. AZTA · Entity 4724 | PurchaseCommon | 4,940 | $40.77 | $201,403.80 |
DisclosureSEC source: 0000950170-24-128541 · ownership.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,405 F1 · price: Represents the weighted average price for the shares purchased. The shares were purchased at per-share prices ranging from $40.59 and $40.90. The reporting person will provide to the SEC, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 22:07 UTC | REPLIGEN CORP RGEN · Entity 486 | PurchaseCommon Stock | 700 | $125.46 | $87,822.00 |
DisclosureSEC source: 0000950170-24-073858 · ownership.xml · nonDerivative · entry 2 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,613 F2 · price: $125.46 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $125.25 to $125.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate purchase price within the range. F3 · ownership.direct: Held by a trust for which the Reporting Person is a trust advisor who shares voting and investment control. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 22:07 UTC | REPLIGEN CORP RGEN · Entity 486 | PurchaseCommon Stock | 915 | $124.54 | $113,954.10 |
DisclosureSEC source: 0000950170-24-073858 · ownership.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,913 F1 · price: $124.54 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $124.25 to $125.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate purchase price within the range. F3 · ownership.direct: Held by a trust for which the Reporting Person is a trust advisor who shares voting and investment control. Read SEC document |
| May 16, 2024 Filed May 20, 2024 23:51 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,376 | $0.00 Strike: $171.03 | $0.00 |
DisclosureSEC source: 0000950170-24-062623 · ownership.xml · derivative · entry 3 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,376 Underlying: Common Stock · 1,376 shares Expires 2034-05-16 F2 · derivative.exercise_date: Award vests in full on the earlier of May 16, 2025, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 16, 2024 Filed May 20, 2024 23:51 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 701 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062623 · ownership.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,998 F1 · shares: Mr. Madaus was awarded 701 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 16, 2025, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 21:10 UTC | Azenta, Inc. AZTA · Entity 4724 | GrantCommon | 2,465 | $65.93 | $162,517.45 |
DisclosureSEC source: 0000950170-24-014564 · ownership.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,465 F1 · shares: Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:09 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (Right to Buy) · Derivative | 6,412 | $0.00 Strike: $27.15 | $0.00 |
DisclosureSEC source: 0001562180-24-000233 · primarydocument.xml · derivative · entry 3 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,412 Underlying: Common Stock · 6,412 shares Expires 2034-01-02 F3 · shares: Represents non-qualified stock option to purchase 6,412 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:09 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 2,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000233 · primarydocument.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,473 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2024 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 2,947 restricted stock units. Read SEC document |
| October 20, 2023 Filed Oct 21, 2023 01:30 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 1,574 | $2.54 | $3,997.96 |
DisclosureSEC source: 0000950170-23-054492 · ownership.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,111 F1 · shares: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest 100% on December 15, 2023. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control. F2 · price: The Restricted Stock Units were issued to the Reporting Person, who elected to take Restricted Stock Units in lieu of $4,000 in cash compensation for services as a committee memeber. The share price is based on the Fair Market Value as of the first date of quarterly trading window following the date on which the Reporting Person's new committe assignment was approved by the Board. F3 · balance_after: Represents Restricted Stock Units with respect to which the Reporting Person has deferred settlement as described above. Read SEC document |
| June 14, 2023 Filed Jun 17, 2023 00:50 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 35,380 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001162194-23-000050 · wk-form4_1686963030.xml · derivative · entry 2 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,380 Underlying: Common Stock · 35,380 shares Expires 2033-06-14 F2 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly increments beginning on July 14, 2023 subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 14, 2023 Filed Jun 17, 2023 00:50 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 26,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-23-000050 · wk-form4_1686963030.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,537 F1 · shares: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest in full on the earlier to occur of June 14, 2024 and one day prior to the date of the Company's next annual meeting of stockholders subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 18, 2023 Filed May 23, 2023 01:48 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,487 | $0.00 Strike: $156.63 | $0.00 |
DisclosureSEC source: 0000899243-23-013695 · doc4.xml · derivative · entry 3 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,487 Underlying: Common Stock · 1,487 shares Expires 2033-05-18 F2 · derivative.exercise_date: Award vests in full on the earlier of May 18, 2024, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 18, 2023 Filed May 23, 2023 01:48 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 686 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-013695 · doc4.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,297 F1 · shares: Mr. Madaus was awarded 686 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 18, 2024, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| May 08, 2023 Filed May 9, 2023 01:15 UTC | REPLIGEN CORP RGEN · Entity 486 | PurchaseCommon Stock | 500 | $156.18 | $78,090.00 |
DisclosureSEC source: 0000899243-23-012433 · doc4.xml · nonDerivative · entry 4 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,611 F4 · price: $156.18 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $156.10 to $156.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate purchase price within the range. F6 · ownership.direct: Held by a trust for which the Reporting Person is a trust advisor who shares voting and investment control. Read SEC document |
| May 05, 2023 Filed May 9, 2023 01:15 UTC | REPLIGEN CORP RGEN · Entity 486 | PurchaseCommon Stock | 500 | $159.19 | $79,595.00 |
DisclosureSEC source: 0000899243-23-012433 · doc4.xml · nonDerivative · entry 3 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,111 F3 · price: $159.19 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $158.96 to $159.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate purchase price within the range. F6 · ownership.direct: Held by a trust for which the Reporting Person is a trust advisor who shares voting and investment control. Read SEC document |
| May 04, 2023 Filed May 9, 2023 01:15 UTC | REPLIGEN CORP RGEN · Entity 486 | PurchaseCommon Stock | 500 | $161.15 | $80,575.00 |
DisclosureSEC source: 0000899243-23-012433 · doc4.xml · nonDerivative · entry 2 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 611 F2 · price: $161.15 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $160.85 to $161.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate purchase price within the range. F6 · ownership.direct: Held by a trust for which the Reporting Person is a trust advisor who shares voting and investment control. Read SEC document |
| March 24, 2023 Filed May 9, 2023 01:15 UTC | REPLIGEN CORP RGEN · Entity 486 | OtherCommon Stock | 11 | $186.22 | $2,048.42 |
DisclosureSEC source: 0000899243-23-012433 · doc4.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 11 F1 · price: $186.22 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $160.14 to $218.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate purchase price within the range. F5 · ownership.nature: Shares held by a revocable trust of which the Reporting Person's spouse serves as trustee. Such shares were unintentionally omitted from the Form 3 originally filed by the Reporting Person on February 8, 2023, and were also omitted from a Form 4 subsequently filed by the Reporting Person on the same date. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Read SEC document |
| February 20, 2023 Filed Feb 23, 2023 02:48 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 29,665 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-23-000006 · wf-form4_167712047950850.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,161 Read SEC document |
| February 06, 2023 Filed Feb 9, 2023 00:24 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,819 | $0.00 Strike: $192.02 | $0.00 |
DisclosureSEC source: 0000899243-23-004343 · doc4.xml · derivative · entry 3 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,819 Underlying: Common Stock · 1,819 shares Expires 2033-02-06 F3 · derivative.exercise_date: The shares vest in equal annual instalments over a three-year period with each such vesting date occurring on the earlier of the anniversary of the grant date or the date of the annual meeting of the Company's shareholders of the applicable year of such three-year period. Read SEC document |
| February 06, 2023 Filed Feb 9, 2023 00:24 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 239 | $0.00 Strike: $192.02 | $0.00 |
DisclosureSEC source: 0000899243-23-004343 · doc4.xml · derivative · entry 2 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239 Underlying: Common Stock · 239 shares Expires 2033-02-06 F2 · derivative.exercise_date: Award vests in full on May 18, 2023, the date of the annual meeting of the Company's shareholders. Read SEC document |
| February 06, 2023 Filed Feb 9, 2023 00:24 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 111 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-004343 · doc4.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111 F1 · shares: Mr. Madaus was awarded 111 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on May 18, 2023, the date of the annual meeting of the Company's shareholders. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:03 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (Right to Buy) · Derivative | 12,124 | $0.00 Strike: $12.86 | $0.00 |
DisclosureSEC source: 0001562180-23-000099 · primarydocument.xml · derivative · entry 3 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,124 Underlying: Common Stock · 12,124 shares Expires 2033-01-03 F3 · shares: Represents non-qualified stock option to purchase 12,124 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated 2018 Non-Employee Director Compensation Policy. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:03 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 8,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000099 · primarydocument.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,526 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2023 granted pursuant to the Quanterix Corporation Amended and Restated 2018 Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 8,083 restricted stock units. Read SEC document |
| August 10, 2022 Filed Aug 10, 2022 22:21 UTC | Quanterix Corp QTRX · Entity 6649 | PurchaseCommon Stock | 89,667 | $8.43 | $755,543.11 |
DisclosureSEC source: 0001562180-22-006032 · primarydocument.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 254,633 F1 · price: This transaction was executed in multiple trades at prices ranging from $8.195 to $8.61. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Held by a trust. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 22:05 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 42,571 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001162194-22-000079 · wf-form4_165550354111671.xml · derivative · entry 2 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,571 Underlying: Common Stock · 42,571 shares Expires 2032-06-15 F2 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly increments beginning on July 15, 2022. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 22:05 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 30,914 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-22-000079 · wf-form4_165550354111671.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,766 F1 · shares: Represents Restricted Stock Units that vest in full on the earlier to occur of June 15, 2023 and one day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 22:35 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 23,401 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001162194-22-000042 · wf-form4_164928449407109.xml · derivative · entry 2 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,401 Underlying: Common Stock · 23,401 shares Expires 2032-04-04 F2 · derivative.exercise_date: The Option becomes exercisable in four equal annual installments beginning on April 4, 2023. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 22:35 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 15,852 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-22-000042 · wf-form4_164928449407109.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,852 F1 · shares: Represents Restricted Stock Units that vest in four equal annual installments beginning April 4, 2023. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:06 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (Right to Buy) · Derivative | 4,002 | $0.00 Strike: $42.41 | $0.00 |
DisclosureSEC source: 0001562180-22-000231 · primarydocument.xml · derivative · entry 4 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,002 Underlying: Common Stock · 4,002 shares Expires 2032-01-03 F6 · shares: Represents non-qualified stock option to purchase 4,002 shares of common stock granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.